Top Markets
#1 DogBull DogBull +105.03%
#2 ADO Protocol ADO Protocol +63.41%
#3 Siacoin Siacoin +46.50%
#4 MarsCoin MarsCoin +37.49%
#5 Useless Coin Useless Coin +36.09%
#6 Ontology Gas Ontology Gas +27.76%
#7 UnifAI Network UnifAI Network +27.18%
#8 Glidr Glidr +19.86%
#9 Falcon Finance Falcon Finance +17.20%
#10 Apertum Apertum +14.82%
Coin of the day
DogBull DogBull
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Clover Biopharmaceuticals, Ltd. Clover Biopharmaceuticals, Ltd.

Clover Biopharmaceuticals, Ltd.

2197
Classifica tra le azioni #15707
Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on... Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.
Prezzo delle azioni
$0.25841098
Capitalizzazione di mercato
$335.38M
Variazione (1 giorno)
-2.42%
Variazione (1 anno)
73.70%
Paese
CN
Scambia Clover Biopharmaceuticals, Ltd. (2197)

Categoria

Healthcare
Rapporto P/B per Clover Biopharmaceuticals, Ltd. (2197)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Clover Biopharmaceuticals, Ltd., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Clover Biopharmaceuticals, Ltd. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.828 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.5116 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 8.2199 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 3.9942 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH